WuXi PharmaTech Announces Third-Quarter EPS of $.30

WuXi PharmaTech Inc. WX today announced its financial results for third-quarter 2010.

Third-Quarter 2010 Highlights

• Net revenues grew 20% year over year to $83.8 million
• China-based Laboratory Services net revenues grew 19% year over year to $57.1  million
• U.S.-based Laboratory Services net revenues increased 20% year over year to $19.6 million
• Manufacturing Services net revenues increased 23% year over year to $7.1 million
• GAAP operating income grew 31% and non-GAAP operating income grew 26% year over year
• GAAP diluted earnings per ADS grew 205% year over year to 59 cents, driven by a strong operating performance and a termination fee relating to the proposed transaction with Charles River Laboratories
• Non-GAAP diluted earnings per ADS grew 26% year over year to 30 cents
• Company increases full-year 2010 guidance for net revenue to $330-$333 million from previous guidance of $320-$325 million
• Company increases full-year 2010 guidance for non-GAAP operating income growth to 28-32% from previous guidance of 15-20%